Transdermal Testosterone Nanoemulsion in Women Libido

Phase 2 Unknown 70 enrolled University Potiguar Farmacias Evidence Ltda · collab Lemos laboratório de Análises Clínicas · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-blind, randomized, placebo-controlled study. Seventy women, aged 35-75 years, with treatment-emergent loss of libido will be randomly allocated to the treatment with a Transdermal nanoemulsion of Testosterone (500mcg) delivering 300 mcg of testosterone/day or an identical placebo nanoemulsion (PLA) for 12 weeks.

Timeline

Start: 2015-10
Primary completion: 2017-10
Completion: 2019-08

Publications

Results Botelho MA, Queiroz DB, Barros G, Guerreiro S, Fechine P, Umbelino S, Lyra A, Borges B, Freitas A, Queiroz DC, Ruela R, Almeida JG, Quintans L Jr. Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study. Clinics (Sao Paulo). 2014 Feb;69(2):75-82. doi: 10.6061/clinics/2014(02)01.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Testosterone	Small molecule	300 ug	Other

Indications

No indication recorded.